recaticimab, a groundbreaking new PCSK9 inhibitor, revolutionizes cholesterol management. Clinical trials demonstrate its efficacy in ⁣significantly lowering bad cholesterol levels, offering a promising new treatment option. This innovative drug introduces flexible dosing, potentially leading to less frequent injections and improved patient adherence to medication. Learn ⁣how this advancement could transform cardiovascular care as reported by News Directory 3. Discover the latest scientific findings from the AHA Scientific Sessions, and‍ explore how ⁤this 3-month medication may redefine treatment strategies, potentially impacting millions. Discover what’s next in the world of cholesterol treatment.